Short Interest in Aptevo Therapeutics Inc. (NASDAQ:APVO) Rises By 675.7%

Posted by Renee Jackson on Nov 13th, 2024

Aptevo Therapeutics Inc. (NASDAQ:APVO – Get Free Report) was the target of a large increase in short interest during the month of October. As of October 31st, there was short interest totalling 1,200,000 shares, an increase of 675.7% from the October 15th total of 154,700 shares. Based on an average daily volume of 6,330,000 shares, the short-interest ratio is presently 0.2 days.

Institutional Investors Weigh In On Aptevo Therapeutics

An institutional investor recently bought a new position in Aptevo Therapeutics stock. Armistice Capital LLC acquired a new position in shares of Aptevo Therapeutics Inc. (NASDAQ:APVO – Free Report) in the second quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 749,234 shares of the biotechnology company’s stock, valued at approximately $229,000. Armistice Capital LLC owned about 18.36% of Aptevo Therapeutics at the end of the most recent quarter. 8.06% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. StockNews.com initiated coverage on Aptevo Therapeutics in a report on Thursday, November 7th. They issued a “sell” rating for the company. Roth Mkm cut their target price on Aptevo Therapeutics from $15.00 to $8.00 and set a “buy” rating for the company in a research note on Monday, September 23rd.

Read Our Latest Stock Report on APVO

Aptevo Therapeutics Stock Down 4.6 %

APVO stock opened at $0.27 on Wednesday. Aptevo Therapeutics has a one year low of $0.14 and a one year high of $10.80. The firm’s 50 day moving average price is $0.24 and its 200-day moving average price is $0.45.

About Aptevo Therapeutics

(Get Free Report)

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.